세계의 심장 마커 검사 시장 : 제품별, 적응증별, 바이오마커 유형별, 최종 사용자별, ASP 및 구매 기준별 - 예측(-2028년)
Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028
상품코드:1373318
리서치사:MarketsandMarkets
발행일:2023년 10월
페이지 정보:영문 216 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
조사 범위
조사 대상년도
2020년-2028년
기준년도
2022년
예측 기간
2023년-2028년
단위
10억 달러
부문
제품별, 적응증별, 바이오마커 유형별, 최종사용자별, 지역별
대상지역
북미, 유럽, 아시아태평양, 라틴아메리카, 중동/아프리카
세계 심장 마커 검사 시장 규모는 2022년 41억 달러에서 2028년 69억 달러에 달할 것으로 예상되며 예측 기간 동안 9.4%의 CAGR을 나타낼 것으로 예상됩니다.
심장 마커 검사 시장의 급격한 성장 전망은 여러 가지 매력적인 장점의 결합에 의해 뒷받침되고 있습니다. 특히, 심장 마커 검사는 인구 고령화, 심혈관 질환에 대한 연구 증가, 새로운 심장 바이오마커를 발견하기 위한 공공 및 민간 기관의 연구 및 자금 지원 이니셔티브 증가가 원동력이 되고 있습니다. 또한, 심장병 진단의 유효성이 향상되고 심부전 질환의 조기 발견이 증가함에 따라 심장 마커 검사가 최전방 솔루션으로 자리 잡으면서 고급 치료법에 대한 수요가 증가하고 있습니다. 이러한 요인의 수렴은 시장 내 강력한 확장 국면을 가져오고, 그 결과 향후 몇 년동안 심장 마커 검사의 채택 상황을 형성할 것으로 보입니다.
바이오마커 유형별로는 트로포닌 I 및 T, 크레아틴 키나아제-MB(CK-MB), 뇌 나트륨 이뇨 펩타이드(BNP 및 NT-PROBNP), 미오글로빈, 고감도 CRP(hs-CRP), 기타 심장 바이오마커로 나뉩니다. 트로포닌 I 및 T 부문은 2022-2028년의 예측 기간 동안 가장 큰 시장 점유율을 기록할 것으로 보입니다. 이 부문의 성장은 뛰어난 민감도와 특이성, 긴 상승 시간(4-8시간에 상승, 10-24시간에 정점에 도달하고 10일 동안 감소), 빠른 결과 예측 등의 요인에 의해 주도되고 있습니다. 또한 검사자들은 다른 바이오마커에 비해 이 마커의 활용에 더 능숙하여 이 분야의 발전에 더욱 박차를 가하고 있습니다.
최종 사용자별로 심장 마커 검사 시장은 실험실, 학술 기관, 현장 검사 기관으로 구분되며, 2022년에는 실험실 부문이 세계 심장 마커 검사 시장에서 61.2%의 가장 큰 점유율을 차지할 것으로 예상됩니다. 이 부문의 성장은 검사 효율성 향상, 현장 검사에 비해 우수한 민감도와 진단 정확도, 현장 검사보다 실험실 검사에 대한 선호도 증가 등의 요인에 의해 주도되고 있습니다.
아태지역 시장은 헬스케어 인프라를 강화하기 위한 신흥국 정부 기관의 투자 증가로 성장세를 보이고 있습니다. 이 외에도 독립적인 임상 검사 기관 증가, 환자 수 증가, 아시아태평양에서 심장 검사 제품 공급을 확대하기 위한 업계 기업들의 전략적 이니셔티브 등이 있습니다.
이 보고서는 세계 심장 마커 검사 시장을 조사했으며, 제품별, 적응증별, 바이오마커 유형별, 최종 사용자별, 지역별 동향, 시장 진출기업 프로파일 등을 정리한 보고서입니다.
Product, biomarker type, diseases, End User, and Region
Regions covered
North America, Europe, Asia Pacific, Latin America and Middle East & Africa
The global cardiac marker testing market is projected to reach USD 6.9 billion by 2028 from USD 4.1 billion in 2022, growing at a CAGR of 9.4% during the forecast period. The projected surge in market growth for cardiac marker testing is underpinned by a confluence of compelling advantages. Notably, cardiac marker testing is driven by aging population, rising cases of cardiovascular diseases, increase in research & funding initiatives from public/private organizations to discover novel cardiac biomarkers. Furthermore, the escalating early detection of heart failure diseases with improved efficacy for diagnosing heart conditions amplifies the demand for advanced treatment modalities, with cardiac marker testing positioned as a forefront solution. This convergence of factors is poised to usher in a phase of robust expansion within the market, consequently shaping the landscape of cardiac marker testing adoption in the forthcoming forecasting years.
"Troponin I and T segment to register largest market share in 2022-2028"
Based on the biomarker type, cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Brain Natriuretic Peptide (BNP and NT-PROBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers. The Troponin I and T segment register a largest market share over the forecast period of 2022-2028. The growth of this segment is propelled by factors such as exceptional sensitivity and specificity, prolonged elevation duration (with levels rising over 4-8 hours, peaking at 10-24 hours, and declining over ten days), and the swift prediction of outcomes. Moreover, lab technicians are more adept at utilizing these markers in comparison to other biomarkers, further fueling the segment's advancement.
"Laboratory testing facilities segment held the largest share of cardiac marker testing market in 2022, by End-user."
Based on the end-user, the cardiac marker testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. In 2022, the laboratory testing facilities segment accounted for the largest share of 61.2% of the global cardiac marker testing market. The growth of this segment is being propelled by factors including increased testing efficiency, superior sensitivity and diagnostic precision in comparison to point-of-care testing, and a strong preference for laboratory testing over point-of-care testing.
"Asia Pacific to register significant growth rate in the market during the forecast period."
For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for cardiac marker testing. There are several drivers that contributed to this growth:
The Asia Pacific market is experiencing growth due to increased investments by government agencies in emerging countries, aimed at enhancing healthcare infrastructure. Additionally, the market is benefiting from the rise in independent clinical laboratories, a substantial patient population, and strategic initiatives by industry players to expand their offerings of cardiac testing products in the Asia Pacific region.
A breakdown of the primary participants referred to for this report is provided below:
By Company Type: Tier 1-43%, Tier 2-30%, and Tier 3- 27%
By Designation: C-level-10%, Director-level-15%, and Others-75%
By Region: North America-40%, Europe-30%, Asia Pacific-23%, Latin America-5%, and the Middle East & Africa-2%
Prominent players in this market are F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), ), Thermo Fisher Scientific Inc. (US) among others.
Research Coverage
The report studies the marker testing market based on products, biomarker type, diseases, end user, and region.
The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
The report studies micro markets with respect to their growth trends, prospects, and contributions to the global cardiac marker testing market
The report forecasts the revenue of market segments with respect to five major regions.
Key Benefits of Buying the Report:
The report will help the new entrants/ market leaders/smaller firms in this market with investment evaluation viability within the cardiac marker testing market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, challenges, growth catalysts and prospects, thereby empowering strategic decision-making with astute discernment.
The report provides insights on the following pointers:
Analysis of key drivers (increasing prevalence of cardiovascular diseases, Increasing geriatric population and subsequent rise in heart conditions worldwide, Ongoing clinical trials for the identification of novel cardiac biomarkers), restraints (Technical issues related to sample collection & storage, Unfavorable regulatory processes and limited reimbursement structure), opportunities (Point-of-care testing (POCT) with cardiac biomarkers, Emerging markets offers high-growth opportunities, Ongoing research on novel cardiac biomarkers for cardiovascular diseases), and challenges (Challenges associated with biomarker assay validation) influencing the growth of the cardiac marker testing market
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the cardiac marker testing market.
Market Development: Comprehensive information about lucrative markets - the report analyses the cardiac marker testing market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cardiac marker testing market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), among others.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY
1.6 RESEARCH LIMITATIONS
1.7 MARKET STAKEHOLDERS
1.8 SUMMARY OF CHANGES
1.8.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH DESIGN
2.2.1 SECONDARY RESEARCH
FIGURE 1 KEY DATA FROM SECONDARY SOURCES
2.2.2 PRIMARY RESEARCH
2.2.2.1 Primary sources
2.2.2.2 Key industry insights
2.2.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.3.1 BOTTOM-UP APPROACH
2.3.2 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
TABLE 125 LSI MEDIENCE CORPORATION: COMPANY OVERVIEW
FIGURE 42 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
12.1.13 QUIDEL CORPORATION
TABLE 126 QUIDEL CORPORATION: COMPANY OVERVIEW
FIGURE 43 QUIDEL CORPORATION: COMPANY SNAPSHOT (2022)
12.1.14 RANDOX LABORATORIES
TABLE 127 RANDOX LABORATORIES: COMPANY OVERVIEW
12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD.
TABLE 128 GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW
12.1.16 BODITECH MED INC.
TABLE 129 BODITECH MED INC.: BUSINESS OVERVIEW
12.1.17 TULIP DIAGNOSTICS (P) LTD.
TABLE 130 TULIP DIAGNOSTICS (P) LTD.: BUSINESS OVERVIEW
12.1.18 BTNX INC.
TABLE 131 BTNX INC.: BUSINESS OVERVIEW
12.1.19 RESPONSE BIOMEDICAL
TABLE 132 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW
12.1.20 ALFA SCIENTIFIC DESIGNS, INC.
TABLE 133 ALFA SCIENTIFIC DESIGNS, INC.: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 CTK BIOTECH, INC.
12.2.2 CREATIVE DIAGNOSTICS
12.2.3 LIFESIGN LLC
12.2.4 CARDIOGENICS HOLDINGS INC.
12.2.5 ATLAS MEDICAL GMBH
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
